key: cord-1022352-jl21k4r3
authors: Dauby, Nicolas
title: Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al
date: 2021-12-11
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.11.026
sha: b879f46477dff84226755f1742a54d562e93574f
doc_id: 1022352
cord_uid: jl21k4r3

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. that are now increasingly reported in international pharmacovigilance databases, including cardiac arrest, bradycardia, and hypotension [3, 4] . Multiple case reports of bradycardia and other electrocardiogram changes have been reported in the literature following RDV administration [5, 6] .Mechanisms of RDV-induced cardiotoxicity are not elucidated but might include alterations in the adenosine metabolism [5] and in vitro data suggest a significant impact of RDV on

ESCMID COVID-19 Living guidelines: drug treatment and clinical management

A living WHO guideline on drugs for covid-19

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns

Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review

Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-The pilot study